News

IUCT-Oncopole and Cell-Easy sign a MOU to accelerate cancer patient access to advanced cell-based therapy IUCT-Oncopole and Cell-Easy announced today the signing of a Memorandum of Understanding to enhance their strategic collaborative relationship and open access to advanced cell-based therapies This partnership aims to drive innovation in public health and improve access to promising new cancer…

Cell-Easy Appoints CDMO Expert Dr. Ribault to Its Board Cell-Easy is a leading contract development and manufacturing organization (CDMO) with a strong foothold in Good Manufacturing Practice (GMP) manufacturing services for immune cells (T, NK cells) and adult stem cells (MSCs, iPSCs) Since 2020, the company keeps expanding into genetically modified cells such as CAR-T…

EMERCell & Cell-Easy sign a Strategic Agreement for the Scale-up and Manufacturing of NK-001 Emercell has selected Cell-Easy as a long-term CDMO partner for the scale-up and manufacturing operations of its allogeneic NK cell-based product, with the objective to enter clinical phase in 2023. Emercell has signed a strategic agreement with Cell-Easy specialized in the…

Cell-Easy Launches OPTI-STEM for Cell Therapy Access The OPTI-STEM consortium led by CDMO Cell-Easy receives €7M from the French government and Bpifrance and €800,000 from the Occitanie Region to democratize access to cell therapy in France and Europe The OPTI-STEM project aims to optimize the production of MSCs in order to democratize access to them…